The UK is regaining its position as a global hub for industry clinical trials, according to the ABPI, but challenges remain in the space.

A trial has shown that belantamab mafodotin can reduce the risk of death by 42% in patients with relapsed or refractory multiple myeloma.

Amgen is investing $1bn to build a second drug substance manufacturing facility in Holly Springs, North Carolina – increasing the company’s total planned investment in the region to more than $1.5bn.

In a victory for people with sickle cell disease, the US government has announced a major step towards improving access to treatment.

Catch up on all the biggest pharma news to hit the industry last month, with stories spanning the US election, new breakthroughs and more.

As the MHRA begins a new chapter, the ABPI has published a report outlining the importance of regulatory excellence in the UK.

The Phase 3 PANOVA-3 trial has shown that adding Tumor Treating Fields therapy to standard chemotherapy improved survival in patients.

Research supported by AstraZeneca has demonstrated that a single dose of benralizumab significantly reduces treatment failure rates – by four times compared to traditional steroid tablets.